Updated Results From DREAMM-3, a Phase 3 Study of Belantamab Mafodotin (Belamaf) Versus Pomalidomide Plus Dexamethasone in Patients (pts) With Relapsed/Refractory Multiple Myeloma (RRMM)

被引：0

作者：

Hungria, Vania T. M. ^{[1
]}

Weisel, Katja ^{[2
]}

Radinoff, Atanas ^{[3
]}

Delimpasi, Sosana ^{[4
]}

Mikala, Gabor ^{[5
]}

Masszi, Tamas ^{[6
]}

Li, Jian ^{[7
]}

Capra, Marcelo ^{[8
]}

Maiolino, Angelo ^{[9
]}

Pappa, Vasiliki ^{[10
]}

Chraniuk, Dominik ^{[11
]}

Osipov, Iurii ^{[12
]}

Leleu, Xavier ^{[13
]}

Low, Michael ^{[14
]}

Kouri, Fotini ^{[15
]}

Liboon, John ^{[16
]}

Brawley, Chris ^{[17
]}

Lewis, Eric ^{[18
]}

Tubel, Gabriela

Li, Mary ^{[18
]}

McKeown, Astrid

Roy-Ghanta, Sumita ^{[18
]}

Opalinska, Joanna ^{[18
]}

Dimopoulos, Meletios ^{[19
]}

机构：

[1] Clin Sao Germano Sao Paulo, Dept Hematol, Sao Paulo, Brazil

[2] Univ Med Ctr Hamburg Eppendorf, Hamburg, Germany

[3] Univ Hosp St Ivan Rilski EAD, Dept Clin Hematol, Sofia, Bulgaria

[4] Gen Hosp Evangelismos, Athens, Greece

[5] Natl Inst Haematol & Infect Dis, Dept Hematol & Stem Cell Transplantat, South Pest Cent Hosp, Budapest, Hungary

[6] Semmelweis Univ, Dept Internal Med & Hematol, Budapest, Hungary

[7] Chinese Acad Med Sci & Peking Union Med Coll, Peking Union Med Coll Hosp, Dept Hematol, Beijing, Peoples R China

[8] Hosp Mae Deus, Ctr Integrado Hematol Oncol, Porto Alegre, RS, Brazil

[9] Inst Amer Ensino Pesquisa & Inovacao, Rio De Janeiro, Brazil

[10] Univ Gen Hosp Attikon, Hematol Unit, Dept Internal Med & Res Unit 2, Athens, Greece

[11] Wojewodzki Szpital Zespolony, Dept Hematol, Torun, Poland

[12] VA Almazov Natl Med Res Ctr, St Petersburg, Russia

[13] CHU Poitiers, PRC, Hematol, Poitiers, France

[14] Clayton Univ, Monash Univ, Monash Hlth, Monash Haematol, Clayton, Vic, Australia

[15] GSK, Stevenage, Herts, England

[16] GSK, San Diego, CA USA

[17] GSK, London, England

[18] GSK, Upper Providence, PA USA

[19] Natl & Kapodistrian Univ Athens, Sch Med, Dept Clin Therapeut, Athens, Greece

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2024年 / 24卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P-395

引用

页码：S261 / S262

页数：2

共 50 条

[21] Belantamab Mafodotin, Pomalidomide, and Dexamethasone vs Pomalidomide, Bortezomib, and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: Patient-Reported Outcomes from DREAMM-8
Dimopoulos, Meletios
Beksac, Meral
Pour, Ludek
Delimpasi, Sosana
Vorobyev, Vladimir
Quach, Hang
Spicka, Ivan
Radocha, Jakub
Robak, Pawel
Kim, Kihyun
Cavo, Michele
Suzuki, Kazuhito
Wilkes, Jodie
Morris, Kristin
Pompilus, Farrah
Purser, Molly
Philips-Jones, Amy
Zhou, Xiaoou
Fulci, Giulia
Sule, Neal
Kremer, Brandon
Opalinska, Joanna
Manteca, Maria-Victoria Mateos
Trudel, Suzanne
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S9 - S9
[22] Belantamab mafodotin (belamaf) for relapsed/refractory multiple myeloma (RRMM): A real-world observational study update
Hultcrantz, Malin
Kleinman, David
Vij, Ravi
Escalante, Fernando
Delforge, Michel
Kotowsky, Nirali
Bitetti, Jacopo
Boytsov, Natalie
Camadoo-O'Byrne, Leena
Powers Happ, Lindsey
Rohman, Mujib
Germain, Guillaume
Duh, Mei Sheng
Laliberte, Francois
Mahendran, Malena
Urosevic, Ana
Lee, Hans C.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[23] Updated Results from a Phase Ib Study of Isatuximab Plus Pomalidomide (Pom) and Dexamethasone (dex) in Relapsed/Refractory Multiple Myeloma (RRMM)
Richardson, Paul G.
Mikhael, Joseph
Usmani, Saad Z.
Raje, Noopur
Bensinger, William
Kanagavel, Dheepak
Gao, Lei
Ziti-Ljajic, Samira
Anderson, Kenneth C.
BLOOD, 2017, 130
[24] A real-world observational study of belantamab mafodotin (belamaf) as a treatment for relapsed/refractory multiple myeloma (RRMM)
Cavo, Michele
Delforge, Michel
Dimopoulos, Meletios
Escalante, Fernando
Hultcrantz, Malin
Kleinman, David
Lee, Hans
Vij, Ravi
Kotowsky, Nirali
Camadoo-O'Byrne, Leena
Bitetti, Jacopo
D'Estrube, Tim
Fry, Mark
Vossen, Carla
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S166 - S167
[25] Dreamm-5 Platform Trial: Belantamab Mafodotin (Belamaf) in Combination with Four Different Novel Agents in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
Richardson, Paul G.
Nooka, Ajay
Quach, Hang
Trudel, Suzanne
Routledge, David
Song, Kevin
Nahi, Hareth
Paul, Sofia
Khan, Josephine
Brouch, Maria
Ferron-Brady, Geraldine
Yeakey, Anne
Shelton, Chris
de Oca, Rocio Montes
Smith, L. Mary
Im, Ellie
Ahlers, Christoph M.
Paul, Elaine M.
Holkova, Beata
Gupta, Ira
Kremer, Brandon E.
Rodriguez-Otero, Paula
BLOOD, 2020, 136
[26] Part 1 Results of a Dose-Finding Study of Belantamab Mafodotin in Combination with Pomalidomide and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma (RRMM)
Trudel, Suzanne
McCurdy, Arleigh
Sutherland, Heather J.
Louzada, Martha L.
Venner, Christopher P.
Mian, Hira S.
Kotb, Rami
Othman, Ibraheem
Camacho, Fernando
Gul, Engin
Reece, Donna E.
White, Darrell J.
Fu, Molei
BLOOD, 2021, 138
[27] Results from Arm A of Phase 1/2 DREAMM-6 trial: belantamab mafodotin with lenalidomide plus dexamethasone in patients with relapsed/refractory multiple myeloma
Popat, Rakesh
Augustson, Bradley
Gironella, Mercedes
Lee, Cindy
Cannell, Paul
Patel, Nashita
Kasinathan, Ravi S.
Rogers, Rachel
Shaikh, Mehreen
Curry, Amy
Carreno, Fernando
Roy-Ghanta, Sumita
Opalinska, Joanna
Quach, Hang
BLOOD CANCER JOURNAL, 2024, 14 (01):
[28] Impact of Long-Term Treatment with Belantamab Mafodotin on Safety and Efficacy Outcomes in Patients with Relapsed/Refractory Multiple Myeloma in DREAMM-3
Hungria, Vania T. M.
Weisel, Katja
Radinoff, Atanas
Delimpasi, Sosana
Mikala, Gabor
Masszi, Tamas
Li, Jian
Capra, Marcelo
Maiolino, Angelo
Pappa, Vasiliki
Chraniuk, Dominik
Osipov, Iurii
Leleu, Xavier
Low, Michael
Matsumoto, Morio
Li, Mary
Sule, Neal
Polinkovsky, Margaret
Davis, Randy
Bright, Shelley
McKeown, Astrid
Opalinska, Joanna
Dimopoulos, Meletios Athanasios
BLOOD, 2023, 142
[29] Impact of baseline ocular conditions (BOCs) on belantamab mafodotin (belamaf)-related corneal events in patients (pts) with relapsed or refractory multiple myeloma (RRMM)
Popat, Rakesh
Kazantzi, Aikaterini
Kleinman, David
Lichenstein, Carolyn
Paka, Prani
Salter, John
Byrne, Julie
Doherty, Allison
Degli Esposti, Simona
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S30 - S30
[30] Patient-Reported Outcomes From the DREAMM-7 Randomized Phase 3 Study Comparing Belantamab Mafodotin (Belamaf), Bortezomib, and Dexamethasone vs Daratumumab, Bortezomib, and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma
Hungria, Vania
Robak, Pawel
Hus, Marek
Fu, ChengCheng
Zherebtsova, Vera
Ward, Christopher
de Almeida, Ana Carolina
Ho, P. Joy
Hajek, Roman
Cerchione, Claudio
Pirooz, Nick
McKeown, Astrid
Baig, Hena
Eccersley, Lydia
Pompilus, Farrah
McNamara, Simon
Lin, Chee Paul
Roy-Ghanta, Sumita
Opalinska, Joanna
Victoria Mateos, Maria
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S568 - S568

← 1 2 3 4 5 →